PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy

BACKGROUND: Immunological checkpoint blockade is effective in treating various malignancies. Identifying predictive biomarkers to assist patient selection for immunotherapy has become a priority in both clinical and research settings. METHODS: Mutations in patients who responded to immunotherapy wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Kien Thiam, Yeh, Chun-Nan, Chang, Yu-Chan, Cheng, Jen-Hao, Fang, Wen-Liang, Yeh, Yi-Chen, Wang, Yu-Chao, Hsu, Dennis Shin-Shian, Wu, Chiao-En, Lai, Jiun-I, Chang, Peter Mu-Hsin, Chen, Ming-Han, Lu, Meng-Lun, Chen, Shu-Jen, Chao, Yee, Hsiao, Michael, Chen, Ming-Huang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174075/
https://www.ncbi.nlm.nih.gov/pubmed/32238472
http://dx.doi.org/10.1136/jitc-2019-000485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174075/
https://www.ncbi.nlm.nih.gov/pubmed/32238472
http://dx.doi.org/10.1136/jitc-2019-000485

Ejemplares similares